Cargando…

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rachiglio, Anna Maria, Fenizia, Francesca, Piccirillo, Maria Carmela, Galetta, Domenico, Crinò, Lucio, Vincenzi, Bruno, Barletta, Emiddio, Pinto, Carmine, Ferraù, Francesco, Lambiase, Matilde, Montanino, Agnese, Roma, Cristin, Ludovini, Vienna, Montagna, Elisabetta Sara, De Luca, Antonella, Rocco, Gaetano, Botti, Gerardo, Perrone, Francesco, Morabito, Alessandro, Normanno, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468673/ https://www.ncbi.nlm.nih.gov/pubmed/30857358 http://dx.doi.org/10.3390/cancers11030341

Ejemplares similares

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology
por: Roma, Cristin, et al.
Publicado: (2013)

RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells
por: De Luca, Antonella, et al.
Publicado: (2014)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2016)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

External quality assessment for EGFR mutations in Italy: improvements in performances over the time
por: Normanno, Nicola, et al.
Publicado: (2017)

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
por: Pasquale, Raffaella, et al.
Publicado: (2020)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells
por: Gallo, Marianna, et al.
Publicado: (2022)

Challenges in bioinformatics approaches to tumor mutation burden analysis
por: Fenizia, Francesca, et al.
Publicado: (2021)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Angiogenesis Inhibitors in Small Cell Lung Cancer
por: Montanino, Agnese, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
por: Siggillino, Annamaria, et al.
Publicado: (2020)

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
por: Ricciuti, Biagio, et al.
Publicado: (2015)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system
por: Rachiglio, Anna Maria, et al.
Publicado: (2021)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Zito Marino, Federica, et al.
Publicado: (2015)

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
por: Palumbo, Giuliano, et al.
Publicado: (2020)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

A Fatal Brain Stroke in Patient with Advanced Breast Cancer Treated with Bevacizumab: A Case Report
por: Domenico, Germano, et al.
Publicado: (2010)

Immunotherapy in Small Cell Lung Cancer
por: Esposito, Giovanna, et al.
Publicado: (2020)

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
por: Roma, Cristin, et al.
Publicado: (2022)

CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study
por: Antognelli, Cinzia, et al.
Publicado: (2009)

Pockets as structural descriptors of EGFR kinase conformations
por: Hasenahuer, Marcia Anahi, et al.
Publicado: (2017)

Erratum to: ‘Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology’
por: Bianconi, Fortunato, et al.
Publicado: (2016)

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis
por: Ludovini, Vienna, et al.
Publicado: (2016)

Correction: Pockets as structural descriptors of EGFR kinase conformations
por: Hasenahuer, Marcia Anahi, et al.
Publicado: (2018)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2022)

Dyskerin and TERC expression may condition survival in lung cancer patients
por: Penzo, Marianna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vmbsv3rc4rj2ueiq7o32r73hcg